Free Cash Flow per Share: A measure of financial performance calculated as operating cash flow minus capital expenditures, expressed on a per share basis. Calculated as: Free Cash Flow / Weighted Average Shares Outstanding (Diluted)
Rapport Therapeutics, Inc. (RAPP) had Free Cash Flow per Share of $-2.26 for the most recently reported fiscal quarter, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
$-33.76M |
|
-- |
|
-- |
|
$38.51M |
|
$-38.51M |
|
$4.75M |
|
$-33.76M |
|
$-33.76M |
|
$-33.76M |
|
$-33.76M |
|
$-33.76M |
|
$-33.76M |
|
$-38.51M |
|
$-39.32M |
|
38.94M |
|
38.94M |
|
$-0.72 |
|
$-0.72 |
|
| Balance Sheet Financials | |
$498.56M |
|
$2.98M |
|
$13.87M |
|
$512.43M |
|
$19.05M |
|
-- |
|
$8.73M |
|
$27.78M |
|
$484.65M |
|
$484.65M |
|
$484.65M |
|
47.77M |
|
| Cash Flow Statement Financials | |
$-87.47M |
|
$-187.47M |
|
$270.79M |
|
$56.91M |
|
$52.75M |
|
$-4.16M |
|
$18.86M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
26.17 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-88.09M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-6.97% |
|
-6.97% |
|
-6.59% |
|
-6.97% |
|
$10.14 |
|
|
Free Cash Flow per Share |
$-2.26 |
$-2.25 |
|